Are there any data for second line nivolumab-ipilimumab in patients with metastatic NSCLC treated with either single agent pembrolizumab or chemotherapy + ICI as first line therapy?
Would you consider second line nivo-ipi for patients with a specific histology or tumor PD-L1 expression?